Sign Out
POL-MOXİ is indicated for the treatment of the following bacterial infections caused by susceptible strains.
Acute exacerbation of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Staphylococcus aureus, Moraxella catarrhalis; Streptococcus pneumoniae (including penicillin-resistant strains with MIC of ≥ 2 μg/ml for penicillin), Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, pneumonia derived from the community; including community-acquired pneumonia caused by multidrug-resistant strains *; *Streptococcus pneumoniae with multiple drug resistance, such as penicillin-resistant S. pneumoniae strains and strains resistant to two or more of the following antibiotics: penicillin (MIC value ≥ 2 μg/ml), 2nd generation cephalosporins (eg, cefuroxime), macrolides, tetracyclines and trimethoprim/sulfamethoxazole; In uncomplicated skin and soft tissue infections caused by Staphylococcus aureus, Streptococcus pyogenes; Complicated skin and soft tissue infections (including diabetic foot) caused by methicillin-sensitive Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae; In complicated intraabdominal infections caused by Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron or Peptostreptococcus spp.
